The introduction of imatinib mesylate, a representative molecular-targeted drug and the first tyrosine kinase inhibitor (TKI) with specific activity against ABL, controls CML in chronic phase. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.